| Followers | 232 |
| Posts | 26887 |
| Boards Moderated | 0 |
| Alias Born | 01/12/2013 |
Tuesday, January 23, 2018 7:03:07 PM
Regarding Amarin v. ITC document 50 being restricted by court.
I contacted JT this AM, Amarin did not request the document be restricted. Amarin is a publicly traded company that has been ransacked by FDA misregulation, this has now led to 3 Federal Court case with direct departments of US Government.
I also contacted PACER and gave brief description of my opinion on the US Government action history, I request the court reconsider their reasoning for restricting the access due to public nature of complaint.
My response from PACER just now:
I think it’s crystal clear the court restricted access; I do however have concerns the court isn’t considering the public damage done to AMRN. The Street doesn’t like uncertainty, it was expected this document would be viewable, who’s to say AMRN wouldn’t have traded up 75% or more on the news today?
Now we’ll never know....discretion will need explaining and I expect Amarin Attorneys file a motion to clear the questions of why the document is restricted.
IMO this isn’t a matter of simply redaction of a few paragraphs, I think the Court has good reason to restrict access and the reasons should be provided in this very public circumstance.
Thanks
BB
I contacted JT this AM, Amarin did not request the document be restricted. Amarin is a publicly traded company that has been ransacked by FDA misregulation, this has now led to 3 Federal Court case with direct departments of US Government.
I also contacted PACER and gave brief description of my opinion on the US Government action history, I request the court reconsider their reasoning for restricting the access due to public nature of complaint.
My response from PACER just now:
The court has at its discretion the option to make certain documents available only to parties in the case. If you are an attorney of record or another party in the case, you must enter your ECF filing ID before trying to access these documents. All others interested in these documents should contact the Court Clerk's office for information about viewing copies, as PACER does not have the ability to provide access to restricted documents.
Thank you,
Matthew
I think it’s crystal clear the court restricted access; I do however have concerns the court isn’t considering the public damage done to AMRN. The Street doesn’t like uncertainty, it was expected this document would be viewable, who’s to say AMRN wouldn’t have traded up 75% or more on the news today?
Now we’ll never know....discretion will need explaining and I expect Amarin Attorneys file a motion to clear the questions of why the document is restricted.
IMO this isn’t a matter of simply redaction of a few paragraphs, I think the Court has good reason to restrict access and the reasons should be provided in this very public circumstance.
Thanks
BB
Mr. McGee, don't make me angry. You wouldn't like me when I'm angry---David Banner
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
